In current meta-analysis, subgroup analysis based on varied cut-off value of MGMT promoter methylation was preformed to address abovementioned issues, and further provide up-to-date clinical evidence for applying MGMT promoter methylation by PSQ as a prognostic biomarker for GBM patients. The gene discussed is MGMT; the disease is glioblastoma.